Observational studyCancer causes & control : CCC2026
Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999-2024.
Observational study in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite major advances in multiple myeloma (MM) therapy including proteasome inhibitors, immunomodulatory agents, anti-CD38 monoclonal antibodies, and chimeric antigen receptor T-cell therapies the extent to which these innovations have translated into equitable population-level mortality reductions across U.S. demographic and geographic subgroups remains unclear. We evaluated national MM mortality trends from 1999-2024 and projected trajectories through 2034, stratified by sex, age, race/ethnicity, census region, urbanization, and place of death.
methodsMM-related deaths were identified from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database using ICD-10 code C90.0 from 1999-2024. Age-adjusted mortality rates (AAMRs) per 1,000,000 population were calculated using the 2000 U.S. standard population. Temporal trends were assessed using joinpoint regression (Joinpoint Regression Program v6.0.1, National Cancer Institute), generating annual percent changes (APCs) and average annual percent changes (AAPCs). Statistical significance was defined as p<0.05. Autoregressive Integrated Moving Average (ARIMA) models selected by Akaike Information Criterion were used to project national and subgroup-specific AAMRs through 2034 with 95% confidence intervals.
resultsFrom 1999-2024, overall MM-related AAMRs declined from 37.6 to 25.1 per 1,000,000 population (AAPC -1.8%; 95% CI -2.1 to -1.5; p<0.001). Mortality decline accelerated significantly after 2012 (APC -3.2%; p<0.001), coinciding with widespread adoption of newer therapeutic agents. Males consistently demonstrated higher AAMRs than females (32.4 vs 19.8 per 1,000,000 in 2024). Black or African American individuals experienced the highest mortality burden throughout the study period, with 2024 AAMRs more than double those of White individuals (48.0 vs 23.5 per 1,000,000). Adults aged ≥65 years had the highest mortality burden (175 per 1,000,000 in 2024, down from 230 in 1999). The South and nonmetropolitan regions consistently showed higher mortality rates than other regions and metropolitan areas. ARIMA projections estimate continued national decline to approximately 20.0 per 1,000,000 (95% CI 17.5-22.5) by 2034, although racial, geographic, and sociodemographic disparities are projected to persist.
conclusionsMM mortality in the United States has declined substantially over the past 25 years, with accelerated improvement after 2012 consistent with the impact of novel therapies. However, major inequities by race, sex, age, geography, and rurality remain and are projected to persist through 2034. Reducing these disparities will require not only continued therapeutic advances but also equitable access to care, earlier diagnosis, and improved representation of underserved populations in clinical research.
Indexed as
Identifiers
42754761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.